These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459 [TBL] [Abstract][Full Text] [Related]
5. Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation. Bisson A; Angoulvant D; Philippart R; Clementy N; Babuty D; Fauchier L Adv Ther; 2017 Jun; 34(6):1283-1290. PubMed ID: 28493056 [TBL] [Abstract][Full Text] [Related]
6. Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Dzeshka MS; Lip GY Expert Opin Pharmacother; 2015; 16(17):2661-78. PubMed ID: 26559069 [TBL] [Abstract][Full Text] [Related]
7. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation. Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111 [TBL] [Abstract][Full Text] [Related]
9. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP; Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380 [TBL] [Abstract][Full Text] [Related]
10. Prevention of stroke in patients with atrial fibrillation. Olsson SB; Halperin JL Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916 [TBL] [Abstract][Full Text] [Related]
11. Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators. Carnicelli AP; Hong H; Giugliano RP; Connolly SJ; Eikelboom J; Patel MR; Wallentin L; Morrow DA; Wojdyla D; Hua K; Hohnloser SH; Oldgren J; Ruff CT; Piccini JP; Lopes RD; Alexander JH; Granger CB; Am Heart J; 2021 Mar; 233():48-58. PubMed ID: 33296688 [TBL] [Abstract][Full Text] [Related]
12. Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation? Reiffel JA Curr Opin Cardiol; 2004 Jan; 19(1):58-63. PubMed ID: 14688636 [TBL] [Abstract][Full Text] [Related]
13. [New anticoagulants for stroke prevention in atrial fibrillation]. Diener HC; Hajjar K; Frank B; Perrey M Herz; 2012 Jun; 37(4):370-7. PubMed ID: 22539096 [TBL] [Abstract][Full Text] [Related]
14. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation. Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801 [No Abstract] [Full Text] [Related]
15. Newer anticoagulants as an alternate to warfarin in atrial fibrillation: a changing paradigm. Chaudhari D; Bhuriya R; Arora R Am J Ther; 2011 Jan; 18(1):e1-e11. PubMed ID: 20460986 [TBL] [Abstract][Full Text] [Related]
16. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261 [TBL] [Abstract][Full Text] [Related]
17. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis. Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583 [TBL] [Abstract][Full Text] [Related]
18. An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs. Deedwania P; Huang GW Rev Cardiovasc Med; 2012; 13(2-3):e89-104. PubMed ID: 23160166 [TBL] [Abstract][Full Text] [Related]
19. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation. Berman JP; Halperin JL Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966 [TBL] [Abstract][Full Text] [Related]
20. Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation. Saliba W Am J Cardiovasc Drugs; 2015 Oct; 15(5):323-35. PubMed ID: 26055615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]